|Brand name(s), other common name(s)||Treanda®|
|Drug type||Alkylating agent|
|How the drug is given||Intravenously (IV)|
Bendamustine is FDA approved to treat people who have chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma (NHL) that has progressed during or within
6 months of treatment with rituximab or a rituximab-containing regimen.
Side effects needing medical attention:Infection, injection reaction, skin reactions.